Status: Recruiting
A Phase I Study in Healthy Volunteers and Parkinson's Disease (PD) Patients.
The goal of this study is to learn if MTX325 can be developed as a potential disease-modifying treatment for Parkinson's Disease.
Participants needed: 106
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Mission TherapeuticsUpdated: Jun 5, 2026Locations: 5
Eligibility criteria
Healthy male and female (Part 1-2 only) participant, aged ≥ 18 to ≤ 55 years. [+35]
A clinically significant history of gastrointestinal disorder likely to influenc... [+56]